LY-487,379

LY-487,379

Clinical data
ATC code	none
Identifiers
IUPAC name N-(4-(2-methoxyphenoxy)phenyl)- N-(2,2,2-trifluoroethylsulfonyl)pyrid- 3-ylmethylamine
PubChem (CID)	9825084
IUPHAR/BPS	1402
ChemSpider	8000831
ChEMBL	CHEMBL108939
Chemical and physical data
Formula	C21H19F3N2O4S
Molar mass	452.446 g/mol
3D model (Jmol)	Interactive image
SMILES c3ncccc3CN(S(=O)(=O)CC(F)(F)F)c2ccc(cc2)Oc1ccccc1OC
InChI InChI=1S/C21H19F3N2O4S/c1-29-19-6-2-3-7-20(19)30-18-10-8-17(9-11-18)26(14-16-5-4-12-25-13-16)31(27,28)15-21(22,23)24/h2-13H,14-15H2,1H3 Key:ALMACYDZFBMGOR-UHFFFAOYSA-N
(what is this?)  (verify)

LY-487,379 is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR₂.^[1] It is used to study the structure and function of this receptor subtype,^[2][3] and LY-487,379 along with various other mGluR_2/3 agonists and positive modulators are being investigated as possible antipsychotic and anxiolytic drugs.^{[4][5][6][7][8]}

See also

• Eglumegad
• HYDIA

References

1. Johnson, M. P.; Baez, M.; Jagdmann, G. E.; Britton, T. C.; Large, T. H.; Callagaro, D. O.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D. (2003). "Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity ofN-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2− trifluoroethylsulfonyl)pyrid-3-ylmethylamine". Journal of Medicinal Chemistry. 46 (15): 3189–3192. doi:10.1021/jm034015u. PMID 12852748.
2. Schaffhauser, H.; Rowe, B. A.; Morales, S.; Chavez-noriega, L. E.; Yin, R.; Jachec, C.; Rao, S. P.; Bain, G.; et al. (2003). "Pharmacological Characterization and Identification of Amino Acids Involved in the Positive Modulation of Metabotropic Glutamate Receptor Subtype 2". Molecular Pharmacology. 64 (4): 798–810. doi:10.1124/mol.64.4.798. PMID 14500736.
3. Poisik, O.; Raju, D. V.; Verreault, M.; Rodriguez, A.; Abeniyi, O. A.; Conn, P. J.; Smith, Y. (2005). "Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus". Neuropharmacology. 49: 57–50. doi:10.1016/j.neuropharm.2005.03.006. PMID 15993439.
4. Galici, R.; Echemendia, N. G.; Rodriguez, A. L.; Conn, P. J. (2005). "A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity". Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1181–7. doi:10.1124/jpet.105.091074. PMID 16123306.
5. Marino; Conn, P. (2006). "Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors". Current Opinion in Pharmacology. 6 (1): 98–102. doi:10.1016/j.coph.2005.09.006. PMID 16368268.
6. Harich; Gross, G.; Bespalov, A. (2007). "Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment". Psychopharmacology. 192 (4): 511–519. doi:10.1007/s00213-007-0742-y. PMID 17318501.
7. Conn, P. J.; Jones, C. K. (2009). "Promise of mGluR2/3 activators in psychiatry". Neuropsychopharmacology. 34 (1): 248–249. doi:10.1038/npp.2008.156. PMC 2907744. PMID 19079073.
8. Hermes, M. L. H. J.; Renaud, L. P. (2010). "Postsynaptic and Presynaptic Group II Metabotropic Glutamate Receptor Activation Reduces Neuronal Excitability in Rat Midline Paraventricular Thalamic Nucleus". Journal of Pharmacology and Experimental Therapeutics. 336 (3): 840–849. doi:10.1124/jpet.110.176149. PMID 21139059.